Short Bowel Syndrome Market Size:

The Short Bowel Syndrome Market size was valued at USD 1.61 billion in 2024 and is expected to reach USD 3.74 billion by 2032, growing at a CAGR of 11.16% over the forecast period of 2025-2032. Rising incidence of gastrointestinal diseases, more incidences of bowel resections, and the growing SBS patient population dependent on parenteral nutrition owing to intestinal failure are driving strong worldwide short bowel syndrome market expansion.

The Crohn's & Colitis Foundation estimates that 10,000 to 20,000 Americans have short bowel syndrome; many of them depend on long-term parenteral support, which causes a major healthcare load. Reflecting high diagnosis rates and adoption of sophisticated short bowel syndrome therapeutics, the U.S. Short Bowel Syndrome market accounted for roughly 79% of the North American market in 2024. Rare illness therapies, including FDA-approved SBS drugs like teduglutide, which have changed the short bowel syndrome therapy market by lowering reliance on parenteral nutrition, have drawn more attention from government health agencies and regulatory authorities. Furthermore, impacting the favourable Short Bowel Syndrome market global development are campaigns raising awareness and better diagnosis.

Usually resulting from bowel resections or congenital abnormalities, Short Bowel Syndrome (SBS) is an uncommon, complicated gastrointestinal disease marked by malabsorption resulting from insufficient functional length of the small intestine. The condition causes major nutritional deficits and dependency on parenteral nutrition. Government health records show a rising global SBS and concomitant intestinal failure incidence. For instance, similar developments have been seen in EU-5 nations; the U.S. boasts a substantial SBS patient population estimated between 15,000 and 20,000. Demand for creative Short Bowel Syndrome drugs and treatments is spurred by this increasing patient load. Reflecting the growing orphan drug market for SBS and continuous clinical trials for Short Bowel Syndrome that concentrate on new medicines to improve patient outcomes and lower complications, regulatory agencies have approved many orphan pharmaceuticals aimed at SBS.

Short Bowel Syndrome Market Dynamics

Drivers

• Tissue Engineering and Regenerative Medicine Advancements Propel Industry Expansion.

The market for short bowel syndrome (SBS) is being much shaped by recent advances in regenerative medicine. Knockout of the SATB2 gene in preclinical mice reprogrammed cells of the upper colon to operate like small intestinal cells, therefore restoring nutrition absorption and reversing weight loss, according to a study published in Gastroenterology in April 2025. This creative method could result in future gene therapies for SBS, providing a possible substitute for small bowel transplants, which have problems, including organ shortage and the necessity of harsh immunosuppression. Funded by the EU, the INTENS initiative aims to overcome the shortfall of donor organs by creating patient-specific jejunal transplants utilizing autologous tissue, therefore removing the need for immunosuppression.

Autologous tissue engineering, a technique employing cells or tissues taken from the same person, is part of the functional bowel rebuilding method. Studies carried out during the project also revealed parallels between the metabolic profiles of the colon scaffolds engineered materials used to generate new tissues for medicinal use—and the small intestine. These parallels imply that the small intestine and colon scaffolds may be used alternatively as platforms for intestinal engineering by scientists. These developments in tissue engineering and regenerative medicine point to a change toward more patient-centric and efficient solutions, hence fueling the growth of the SBS treatment market.

Restraints

• High Treatment Costs and Limited Access Restrain Market Growth

Though there are now more treatment choices, the great expenses related to SBS management still greatly limit market expansion. The main course of treatment for SBS is nutrition support, which can be somewhat costly, involving parenteral nourishment. Furthermore, the complexity of addressing SBS via multidisciplinary approaches calls for significant healthcare infrastructure and knowledge, which might not always be available, thus limiting market expansion. Some people with short bowel syndrome may get pancreatic enzyme replacement therapy, including bile-acid resins such as cholestyramine and pancrelipase. Though non-transplant and transplant operations sometimes define surgical choices for short bowel syndrome, as surgical skills advance, they may finally be deemed a front-line solution. Many patients may find it difficult to get the required treatment without enough financial support and easily available healthcare resources, thereby restricting the total potential growth of the SBS market.

Short Bowel Syndrome Market Segmentation Analysis

By Type

The GLP-2 segment dominated the SBS market in 2024 with a dominant 94% revenue share, driven by the great acceptance of FDA-approved medications such as teduglutide (marketed as Gattex/Revestive). Analogues of glucagon-like peptide-2 (GLP-2), Teduglutide, improve the quality of life for SBS patients by lowering parenteral nutrition reliance and increasing intestinal absorption. Government regulatory approvals and orphan drug designations have strengthened the legitimacy of GLP-2 therapies and helped them to be more widely used, particularly in developed areas like the United States and Europe. Recent clinical trials, including phase 2 and 3 investigations of new GLP-2 analogues such as apraglutide and glepaglutide, highlight the great R&D effort on expanding the SBS pipeline drugs portfolio, hence driving market growth for Short Bowel Syndrome.

On the other hand, the growth hormone segment is expected to rise greatly since it might raise lean body mass and body weight in SBS patients. Still, adverse problems and inadequate adult efficacy data help to restrain its acceptance. Future use in both adult and pediatric SBS populations is predicted to be driven by continuous research on refining growth hormone therapy regimens to increase safety and efficacy, highlighted in government health reports.

By Distribution Channel

Driven by growing patient demand for quick access to drugs and the development of e-commerce platforms in healthcare, the online and retail pharmacy sector led the SBS treatment market in 2024. The emergence of telemedicine and home healthcare specialty clinics has helped this trend to be encouraged even more by allowing patients with intestinal failure to control their condition remotely, and hence lower hospital visits.  Especially in industrialized nations, government healthcare projects encouraging digital health uptake and remote patient monitoring have sped this change.

The hospital pharmacies are predicted to expand noticeably during the projection period as more complicated SBS patients needing specialized therapies and acute care increase demand. Administering parenteral nourishment and controlling SBS-related problems depend on hospitals, which remain indispensable. Rising hospitalization rates for SBS patients shown by government healthcare data from the United States and Europe, promote the development of hospital pharmacy services specifically targeted to SBS treatments. Recent advances include improved SBS patient outcomes and demand for hospital-dispensed medications employing integration of multidisciplinary care models and improved clinical protocols in hospitals.

Short Bowel Syndrome Market Regional Outlook

North America region dominated the market with held 72% market share and is valued at USD 1.16 billion, the global short bowel syndrome (SBS) market in 2024 is expected to grow significantly. By 2032, the U.S. short bowel syndrome market size is expected to rise to USD 2.09 billion. Strong government funding for rare illness therapies, advanced healthcare infrastructure, and a sizable SBS patient population drive this predominance mostly. The Crohn's & Colitis Foundation estimates that SBS affects 10,000 to 20,000 people in the United States; many of them need parenteral nutrition as intestinal failure results. Funding for SBS research has been raised by the US government, best shown by a 2021 NIH grant of USD 1.9 million to investigate new drugs aiming at SBS-related multisystem damage. This money promotes strong short bowel syndrome market expansion in the area, together with high adoption rates of FDA-approved SBS drugs such as teduglutide.

With the second-largest percentage of the global SBS market, Europe is Along with thorough patient care systems, the presence of new biotechnology businesses emphasizing creative SBS therapies and biologics drives market growth. Particularly for GLP-2 analogues, which are fundamental for the short bowel syndrome therapeutics market, the area gains from a well-established healthcare system and rising clinical trials for short bowel syndrome.

The forecast period shows Asia Pacific to be the fastest-growing area, predicted to have the greatest CAGR. Rising awareness of rare diseases in nations such as India, Japan, and Australia, along with increasing R&D spending and expanding GLP-2-based medication clinical trials, supports this expansion. Key elements increasing the worldwide short bowel syndrome market growth in this area are the direct presence of big pharmaceutical corporations and expanding healthcare infrastructure. Since SBS is underdiagnosed in many areas of Asia, government projects targeted at enhancing diagnosis and treatment access are further driving the market.

Rising awareness and bettering healthcare infrastructure are helping Latin America and the Middle East and Africa (LAMEA) areas to see slow development. Still, market penetration is small when compared to North America and Europe. Supported by government health initiatives concentrating on uncommon diseases and gastrointestinal disorders, efforts to increase distribution channels and deliver new SBS therapies are continuous.

Key Players in the Short Bowel Syndrome Market

The key Short Bowel Syndrome Companies are Swedish Orphan Biovitrum AB, Emmaus Life Sciences, Inc., OxThera AB, Merck & Co., Inc., Novartis AG, Wellspect Healthcare (Dentsply Sirona Company), OPKO Health, Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and others

Recent Developments in the Short Bowel Syndrome Market

• The worldwide SBS market is estimated to reach USD 6.4 billion by 2030 from USD 2 billion in 2024. Advances in home healthcare and telemedicine complement the predicted expansion that GLP-2 medications bring about.

• Phase 2 clinical trials were cleared by Hanmi Pharmaceutical's GLP-2 analogue HM15912 in January 2025, thereby greatly changing the SBS pipeline pharmaceuticals scene.